Evidence map›Paper›PMID 37231729›Full record

ReviewCurrent medicinal chemistry2024

Drug Delivery Systems based on Microneedles for Dermatological Diseases and Aesthetic Enhancement.

Mariane Massufero Vergilio, James Caradoc Birchall, Lonetá Lauro Lima, Rodrigo Alvarenga Rezende, Gislaine Ricci Leonardi

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Mariane Massufero VergilioGraduate Program in Internal Medicine, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, SP, Brazil.ORCID 0000-0001-5979-8860
James Caradoc BirchallSchool of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, CF10 3NB, UK.ORCID 0000-0001-8521-6924
Lonetá Lauro Lima3D Technologies Research Group, NT3D, Renato Archer Information Technology Center (CTI), Campinas, SP, Brazi.ORCID 0000-0002-2214-7148
Rodrigo Alvarenga Rezende3D Technologies Research Group, NT3D, Renato Archer Information Technology Center (CTI), Campinas, SP, Brazi.ORCID 0000-0002-6604-5880
Gislaine Ricci LeonardiGraduate Program in Internal Medicine, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, SP, Brazil.ORCID 0000-0002-7126-1326
Centro de Tecnologia da Informação Renato Archer · BRUniversidade Estadual de Campinas (UNICAMP) · BRCardiff University · GB

Funding

National Council for the Improvement of Higher Education 0001São Paulo Research Foundation (FAPESP) 2020/08516-0
6 · The paper itself

Abstract

Microneedle (MN) devices comprise of micron-sized structures that circumvent biological barriers in a minimally invasive manner. MN research continues to grow and evolve; the technology was recently identified as one of the top ten overall emerging technologies of 2020. There is a growing interest in using such devices in cosmetology and dermatological conditions where the MNs mechanically disrupt the outer skin barrier layer, creating transient pathways that allow the passage of materials to underlying skin layers. This review aims to appraise the application of microneedle technologies in skin science, provide information on potential clinical benefits, as well as indicate possible dermatological conditions that can benefit from this technology, including autoimmunemediated inflammatory skin diseases, skin aging, hyperpigmentation, and skin tumors. A literature review was carried out to select studies that evaluated the use of microneedles to enhance drug delivery for dermatologic purposes. MN patches create temporary pathways that allow the passage of therapeutic material to deeper layers of the skin. Given their demonstrable promise in therapeutic applications it will be essential for healthcare professionals to engage with these new delivery systems as they transition to the clinic.

Indexed as

Drug Delivery SystemsNeedlesSkin DiseasesAdministration, CutaneousAnimalsHumansMicroinjectionsaesthetic enhancementbiological barriersdermatological disease.diseased skinDrug deliverymicroneedle

Identifiers

PMID37231729
OpenAlexW4378348547

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.